Eli Lilly is making a late leap into the cholesterol-lowering drug market.

The company said this morning it is launching a new drug in the U.S. this month called Livalo, in partnership with Kowa Co. of Japan. The move comes just six months after the two companies signed a licensing agreement, and represents Lilly’s biggest push into a new area in years.

The market for cholesterol drugs is huge. Last year, physicians wrote more than 200 million prescriptions for cholesterol drugs, generating about $13 billion in sales for drugmakers, making it largest class of drugs worldwide.

But some analysts question whether the company is late to the game. The market is crowded with competing products, including some the top-selling drugs in the world, such as Lipitor and Crestor.

Some analysts say the market for statins already has peaked and prices are falling as more

Once a leading producer of mint, Indiana has slipped to fourth due to both domestic consolidation and foreign competition.

NIPSCO is still working to restore power to thousands of residents in northern Indiana after fierce thunderstorms blew through the region last Friday.

The city of Jefferson is considering the creation of a new construction inspector position

A Florida-based fish farm operator has dropped Russiaville from its expansion plans because of local opposition to its proposed presence.